Quantitative evaluation and optimization of co-drugging to improve anti-HIV latency therapy

Cellular and Molecular Bioengineering

Volumn 7, Issue 3, 2014, Pages 320-333

  Wong, Victor C ^a   Fong, Linda E ^b   Adams, Nicholas M ^b   Xue, Qiong ^b   Dey, Siddharth S ^c,d   Miller Jensen, Kathryn ^a  

^a YALE UNIVERSITY   (United States)

^b Yale University   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Drug synergy; Histone deacetylase inhibitors; HIV latency; NF kB

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HEXAMETHYLENEBISACETAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTRATIN; PROTEIN KINASE C ACTIVATOR; TRANSCRIPTION FACTOR RELA; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VORINOSTAT;

ANTI HIV LATENCY THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CELL DEATH; CHROMATIN; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LATENT VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS ACTIVATION; VIRUS GENE; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84906935485     PISSN: 18655025     EISSN: 18655033     Source Type: Journal    
DOI: 10.1007/s12195-014-0336-9     Document Type: Article

References (44)

1. Archin, N. M., A. L. Liberty, A. D. Kashuba, S. K. Choudhary, J. D. Kuruc, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485, 2012.
2. Barboric, M., J. H. N. Yik, N. Czudnochowski, Z. Yang, R. Chen, et al. Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Res. 35:2003-2012, 2007. (Pubitemid 47061666)
3. Blazkova, J., K. Trejbalova, F. Gondois-Rey, P. Halfon, P. Philibert, et al. CpG Methylation Controls Reactivation of HIV from Latency. PLoS Pathog. 5:e1000554, 2009.
4. Bliss, C. I. The calculation of microbial assays. Bacteriol. Rev. 20:243-258, 1956.
5. Böhnlein, E., J. W. Lowenthal, M. Siekevitz, D. W. Ballard, B. R. Franza, et al. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell 53:827-836, 1988.
6. Bosque, A., and V. Planelles. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113:58-65, 2009.
7. Bosque, A., and V. Planelles. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods 53:54-61, 2011.
8. Bullen, C. K., G. M. Laird, C. M. Durand, J. D. Siliciano, and R. F. Siliciano. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 20:425-429, 2014.
9. Burnett, J. C., K.-I. Lim, A. Calafi, J. J. Rossi, D. V. Schaffer, et al. Combinatorial latency reactivation for HIV-1 subtypes and variants. J. Virol. 84:5958-5974, 2010.
10. Burnett, J. C., K. Miller-Jensen, P. S. Shah, A. P. Arkin, and D. V. Schaffer. Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog. 5:e1000260, 2009.
11. Choudhary, S. K., N. M. Archin, and D. M. Margolis. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J. Infect. Dis. 197:1162-1170, 2008. (Pubitemid 351590052)
12. Contreras, X., M. Barboric, T. Lenasi, and B. M. Peterlin. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog. 3:1459-1469, 2007. (Pubitemid 350085610)
13. Contreras, X., M. Schweneker, C. S. Chen, J. M. McCune, S. G. Deeks, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284:6782-6789, 2009.
14. Coull, J. J., F. Romerio, J. M. Sun, J. L. Volker, K. M. Galvin, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74:6790-6799, 2000. (Pubitemid 30470662)
15. Duh, E. J., W. J. Maury, T. M. Folks, A. S. Fauci, and A. B. Rabson. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 86:5974-5978, 1989. (Pubitemid 19217570)
16. Durand, C. M., J. N. Blankson, and R. F. Siliciano. Developing strategies for HIV-1 eradication. Trends Immunol. 33:554-562, 2012.
17. Emiliani, S., C. Van Lint, W. Fischle, P. Paras, Jr., M. Ott, et al. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc. Natl. Acad. Sci. USA 93:6377-6381, 1996. (Pubitemid 26230313)
18. Fernandez, G., and S. L. Zeichner. Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol. J. 7:266, 2010.
19. Finzi, D., J. Blankson, J. D. Siliciano, J. B. Margolick, K. Chadwick, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517, 1999. (Pubitemid 29220209)
20. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300, 1997. (Pubitemid 27495742)
21. Fitzgerald, J. B., B. Schoeberl, U. B. Nielsen, and P. K. Sorger. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2:458-466, 2006. (Pubitemid 44266307)
22. Ganesh, L., E. Burstein, A. Guha-Niyogi, M. K. Louder, J. R. Mascola, et al. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 426:853-857, 2003. (Pubitemid 38056872)
23. Han, Y., K. Lassen, D. Monie, A. R. Sedaghat, S. Shimoji, et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78:6122-6133, 2004. (Pubitemid 38715910)
24. Ho, Y. C., L. Shan, N. N. Hosmane, J. Wang, S. B. Laskey, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551, 2013.
25. Jiang, G., A. Espeseth, D. J. Hazuda, and D. M. Margolis. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J. Virol. 81:10914-10923, 2007. (Pubitemid 47536066)
26. Jordan, A., D. Bisgrove, and E. Verdin. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22:1868-1877, 2003. (Pubitemid 36460143)
27. Kao, S. Y., A. F. Calman, P. A. Luciw, and B. M. Peterlin. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330:489-493, 1987.
28. Kasowski, M., S. Kyriazopoulou-Panagiotopoulou, F. Grubert, J. B. Zaugg, A. Kundaje, et al. Extensive variation in chromatin states across humans. Science 342:750-752, 2013.
29. Kauder, S. E., A. Bosque, A. Lindqvist, V. Planelles, and E. Verdin. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5:e1000495, 2009.
30. Kim, Y. K., C. F. Bourgeois, R. Pearson, M. Tyagi, M. J. West, et al. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J. 25:1-9, 2006.
31. Kinoshita, S., L. Su, M. Amano, L. A. Timmerman, H. Kaneshima, et al. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 6:235-244, 1997. (Pubitemid 27148590)
32. Miller-Jensen, K., S. S. Dey, N. Pham, J. E. Foley, A. P. Arkin, et al. Chromatin accessibility at the HIV LTR promoter sets a threshold for NF-kappaB mediated viral gene expression. Integr. Biol. (Camb.) 4:661-671, 2012.
33. Miller-Jensen, K., R. Skupsky, P. S. Shah, A. P. Arkin, and D. V. Schaffer. Genetic selection for context-dependent stochastic phenotypes: Sp1 and TATA mutations increase phenotypic noise in HIV-1 gene expression. PLoS Comput. Biol. 9:e1003135, 2013.
34. Nabel, G., and D. Baltimore. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713, 1987. (Pubitemid 17059793)
35. Ott, M., M. Geyer, and Q. Zhou. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 10:426-435, 2011.
36. Quivy, V., E. Adam, Y. Collette, D. Demonte, A. Chariot, et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J. Virol. 76:11091-11103, 2002. (Pubitemid 35176225)
37. Reuse, S., M. Calao, K. Kabeya, A. Guiguen, J.-S. Gatot, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 4:e6093, 2009.
38. Richman, D. D., D. M. Margolis, M. Delaney, W. C. Greene, D. Hazuda, et al. The challenge of finding a cure for HIV infection. Science 323:1304-1307, 2009.
39. Rowinsky, E. K., D. S. Ettinger, L. B. Grochow, R. B. Brundrett, A. E. Cates, et al. Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer. J. Clin. Oncol. 4:1835-1844, 1986. (Pubitemid 17226675)
40. Selby, M. J., and B. M. Peterlin. Trans-activation by HIV-1 Tat via a heterologous RNA binding protein. Cell 62:769-776, 1990.
41. Tyagi, M., and J. Karn. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 26:4985-4995, 2007. (Pubitemid 350261291)
42. Tyagi, M., R. J. Pearson, and J. Karn. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84:6425-6437, 2010.
43. Weinberger, L. S., J. C. Burnett, J. E. Toettcher, A. P. Arkin, and D. V. Schaffer. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122:169-182, 2005. (Pubitemid 41032982)
44. Williams, S. A., L.-F. Chen, H. Kwon, C. M. Ruiz-Jarabo, E. Verdin, et al. NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-149, 2006. (Pubitemid 43077303)